November 30, 2022
The UNC School of Medicine lab of Bryan L. Roth, MD, PhD, solved the high-resolution, complex structures of drug-like compounds bound to designer brain cell receptors, paving the way for the creation of next-generation chemogenetic tools. Postdoc Shicheng Zhang, PhD, led this research published in Nature.
November 29, 2022
Led by Jin Szatkiewicz, PhD, UNC School of Medicine researchers and University of Toronto colleagues found that a rare form of a common genetic variant called tandem repeats is strongly associated with the development of schizophrenia.
November 21, 2022
A new glioblastoma treatment from Northwest Biotherapeutics improved outcomes for many patients in a phase 3 clinical study, according to a study published in JAMA Oncology. Matt Ewend, MD, in the UNC Department of Neurosurgery and at UNC Lineberger, led the trial site at the N.C. Basnight Cancer Hospital.
November 2, 2022
Researchers at the UNC School of Medicine led by Justin Wolter, PhD, and colleagues at the UNC Eshelman School of Pharmacy and Queen Mary University of London, teamed up to publish a comprehensive analysis of what goes awry in brain cells lacking the sacsin protein.
October 27, 2022
UNC Institute for Global Health and Infectious Diseases and critical care experts William Fischer, MD, and David Wohl, MD, in collaboration with UNC Hospitals colleagues, will lead a Regional Emerging Special Pathogen Treatment Center funded through the U.S. Department of Health and Human Services' Administration for Strategic Preparedness and Response.
October 11, 2022
A new North Carolina study called VISION is now underway to answer some of the biggest questions about COVID-19. Led by William Fischer, MD, principal investigator, and David Wohl, MD, co-lead, the study plans to enroll 7,500 COVID-positive individuals to understand the different factors that impact individual risk for key clinical outcomes including recovery from acute illness, symptom rebound, re-infection, and long COVID. Investigators explain the study more in video.
September 29, 2022
The $8-million dollar DISENTANGLE initiative, led by Sam McLean, MD, MPH, at the UNC School of Medicine and funded through the U.S. Department of Defense, will leverage the latest data on brain injury biomarkers and clinical observations to prevent and treat severe posttraumatic symptoms.
September 28, 2022
A research team from UNC-Chapel Hill, UC San Francisco, Yale, Duke, and Stanford developed a new compound that hits the same brain cell target as psychedelic drugs, triggering long-lasting anti-depressant action without psychedelic effects in mice.
September 22, 2022
The national GRADE study, with leadership and participation from UNC School of Medicine's John Buse, MD, PhD, and Sue Kirkman, MD, found that two of four common type 2 diabetes treatments -- glargine and liraglutide -- worked better than the other drugs, sitagliptin and glimepiride, to maintain blood glucose levels.
September 12, 2022
Joe Piven, MD, director of the Carolina Institute for Developmental Disabilities, is the principal investigator on a 5-year, $12-million NIH grant for the Brain and Behavior Study of ASD from Infancy through Adolescence, led by UNC School of Medicine researchers.
August 8, 2022
Led by Martina Kovarova, PhD, Miriam Braunstein, PhD, and J. Victor Garcia, PhD, UNC School of Medicine researchers showed in vivo efficacy of a long-acting injectable formulation of the anti-TB drug rifabutin.
July 27, 2022
The UNC School of Medicine lab of Bryan Roth, MD, PhD, found variants in one tiny serotonin receptor in neurons, and these variants could be why some patients fare much better after psychedelic therapy than other patients.